Skip to main content
Premium Trial:

Request an Annual Quote

David Thorpe, John Clouston, Leonard Keenan, John Abeles

Premium
David Thorpe, John Clouston, and Leonard Keenan have joined Ariadne Genomics’ North American and European sales teams, the company said this week.
 
Clouston joins Ariadne as sales manager in the North American market. Previously, he held a similar position at Silicon Genetics (now GeneSpring at Agilent Technologies).
 
Thorpe has been appointed director of enterprise sales and will lead corporate and enterprise sales efforts in North America and Europe. He held senior-level positions at OriGene Technologies, CambridgeSoft, and InforMax (now Invitrogen).
 
Keenan serves as business development associate for the European market. He previously held business development and sales management positions at a variety of software companies.
 

 
John Abeles joined CombiMatrix’s Scientific Advisory Board, parent company Acacia Research said this week.
 
Abeles practiced medicine in London before becoming a senior executive at Pfizer, Sterling Drug, and Revlon Health Care. He was a healthcare analyst with Kidder Peabody and later formed MedVest, a healthcare consulting firm. He was a healthcare analyst with and later formed, a healthcare consulting firm.
 
Abeles received his medical degree as well as a degree in pharmacology from the University of Birmingham, UK

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.